Drugs / BLB-201
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05281263 | Jul → Dec 2022 | respiratory syncytial virus infectious disease | Blue Lake Biotechnology Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05655182 | Mar 2023 → Dec 2028 expected | respiratory syncytial virus infectious disease | Blue Lake Biotechnology Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BLB201 | “This first in-human clinical trial evaluated a single dose of BLB201, a PIV5-vectored RSV vaccine administrated via intranasal route” PMID 37878713 ↗ Oct 2023 |
| Known as | CPI-RSV-F Vaccine | “CPI-RSV-F Vaccine (BLB-201)” NCT05281263 ↗ |
| Modality | Vaccine | “BLB201, a PIV5-vectored RSV vaccine” PMID 37878713 ↗ Oct 2023 |
| Route | Intranasal | “administrated via intranasal route” PMID 37878713 ↗ Oct 2023 |